Lord, Abbett & Co
NBIX icon

Lord, Abbett & Co’s Neurocrine Biosciences NBIX Stock Holding History

Lord, Abbett & Co’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-34,443
Closed -$4.74M – 580
2024
Q2 		$4.74M Sell
34,443
-356,801
-91% -$48.9M 0.02% 468
2024
Q1 		$54M Buy
391,244
+344,263
+733% +$47M 0.17% 161
2023
Q4 		$6.19M Buy
+46,981
New +$5.41M 0.02% 439
2023
Q1 		– Sell
-2,598
Closed -$311K – 614
2022
Q4 		$311K Buy
+2,598
New +$304K ﹤0.01% 565
2020
Q2 		– Sell
-67,163
Closed -$5.81M – 676
2020
Q1 		$5.81M Sell
67,163
-15,943
-19% -$1.56M 0.03% 512
2019
Q4 		$8.93M Sell
83,106
-11,355
-12% -$1.19M 0.03% 540
2019
Q3 		$8.51M Buy
94,461
+157
+0.2% +$14.7K 0.03% 556
2019
Q2 		$7.96M Buy
94,304
+36,477
+63% +$3M 0.03% 600
2019
Q1 		$5.09M Buy
57,827
+1,443
+3% +$121K 0.02% 649
2018
Q4 		$4.03M Sell
56,384
-3,019
-5% -$289K 0.01% 682
2018
Q3 		$7.3M Buy
+59,403
New +$6.74M 0.02% 676
2016
Q4 		– Sell
-345,748
Closed -$17.5M – 928
2016
Q3 		$17.5M Sell
345,748
-99,139
-22% -$4.94M 0.05% 457
2016
Q2 		$20.2M Buy
+444,887
New +$20.5M 0.06% 415
2016
Q1 		– Sell
-584,280
Closed -$33.1M – 922
2015
Q4 		$33.1M Buy
584,280
+56,098
+11% +$2.85M 0.1% 320
2015
Q3 		$21M Sell
528,182
-40,000
-7% -$1.93M 0.06% 411
2015
Q2 		$27.1M Sell
568,182
-419,402
-42% -$17.8M 0.07% 397
2015
Q1 		$39.2M Buy
987,584
+753,717
+322% +$27M 0.1% 318
2014
Q4 		$5.22M Sell
233,867
-87,921
-27% -$1.67M 0.01% 724
2014
Q3 		$5.04M Buy
321,788
+5,420
+2% +$81K 0.01% 745
2014
Q2 		$4.7M Buy
316,368
+79,227
+33% +$1.12M 0.01% 815
2014
Q1 		$3.82M Buy
+237,141
New +$4.06M 0.01% 833
2013
Q3 		– Sell
-376,503
Closed -$5.04M – 1078
2013
Q2 		$5.04M Buy
+376,503
New +$4.63M 0.01% 801

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Lord, Abbett & Co's NBIX Position: Q3 2024 in Review

Lord, Abbett & Co sold out of Neurocrine Biosciences (NBIX) in Q3 2024, closing a stake of 34,443 shares — an estimated $4.74M sold.

Lord, Abbett & Co first reported a position in NBIX in Q2 2013 and held it in 22 quarters. The position peaked at $54M in Q1 2024. 574 funds tracked by Wall St. Rank hold NBIX as of Q3 2024.

  • Lord, Abbett & Co reported no remaining Neurocrine Biosciences position as of Q3 2024 after selling out during the quarter.
  • Lord, Abbett & Co sold 34,443 Neurocrine Biosciences shares in Q3 2024, an estimated $4.74M.
  • Lord, Abbett & Co first reported a position in Neurocrine Biosciences in Q2 2013 and held it in 22 quarters.
  • Lord, Abbett & Co's Neurocrine Biosciences position peaked at $54M in Q1 2024.
  • 574 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2024.

Based on Lord, Abbett & Co's 13F filing for Q3 2024, filed 14 Nov 2024.